Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are currently covering the stock, ...

Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Finding an employer that aligns with your values, work style, and career aspirations is more important than ever.

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Anti-Fungal Therapy Market. The global anti-fungal therapy market is set to experience significant growth, with a projected ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

For Hoosiers seeking a fresh start or a pathway to a fulfilling career, the Lilly Scholars at Ivy Tech scholarships offer a ...

Attorney General Keith Ellison reached a settlement with insulin manufacturers Eli Lilly, Sanofi, and Novo Nordisk, which ...